Identifying Clinicopathological Factors Associated with Oncotype DX<sup>®</sup> 21-Gene Recurrence Score: A Real-World Retrospective Cohort Study of Breast Cancer Patients in Quebec City, Canada

Identifying Clinicopathological Factors Associated with Oncotype DX<sup>®</sup> 21-Gene Recurrence Score: A Real-World Retrospective Cohort Study of Breast Cancer Patients in Quebec City, Canada

Gene expression profiling tests such as the Oncotype DX (ODX) 21-gene recurrence score (RS) assay is increasingly used in clinical practice to predict the risk of recurrence and support treatment planning for early-stage breast cancer (BC). However, this test has some disadvantages such as a high co...

Full description

Bibliographic Details
Main Authors:	Simon Gagnet, Caroline Diorio, Louise Provencher, Cynthia Mbuya-Bienge, Julie Lapointe, Claudya Morin, Julie Lemieux, Hermann Nabi
Format:	Article
Language:	English
Published:	MDPI AG 2021-08-01
Series:	Journal of Personalized Medicine
Subjects:	adjuvant chemotherapy breast cancer subtype cancer recurrence risk score clinical decision making gene expression profiling lifestyle risk factors
Online Access:	https://www.mdpi.com/2075-4426/11/9/858

Similar Items

Spotlight on the utility of the Oncotype DX® breast cancer assay
by: Siow ZR, et al.
Published: (2018-02-01)

Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use
by: Evelien Schaafsma, et al.
Published: (2021-07-01)

Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016
by: Thomas M. Schwedhelm, et al.
Published: (2020-09-01)

The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real‐world early‐stage breast cancer
by: Daniel A. Goldstein, et al.
Published: (2020-07-01)

Background Parenchymal Enhancement on Breast MRI as a Prognostic Surrogate: Correlation With Breast Cancer Oncotype Dx Score
by: Michelle Zhang, et al.
Published: (2021-02-01)

Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online
by: Beate Jahn, et al.
Published: (2017-10-01)

Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center
by: Salah Fayaz, et al.
Published: (2020-03-01)

How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
by: Xiaofu Zhu, et al.
Published: (2021-02-01)

Results of combination treatment using docetaxel in an adjuvant chemotherapy regimen for resectable breast cancer
by: L. V. Bolotina, et al.
Published: (2014-07-01)

ADJUVANT CHEMOTHERAPY OF PRIMARY OPERABLE LUMINAL B BREAST CANCER WITHOUT OVEREXPRESSION OF HER2/NEU IN POSTMENOPAUSAL WOMEN: YES OR NO?
by: Yu. S. Shatova, et al.
Published: (2017-12-01)

Choice of adjuvant drug therapy on the basis of the molecular classification of breast cancer
by: N. S. Besova
Published: (2014-07-01)

Oncotype DX Test Receipt among Latina/Hispanic Women with Early Invasive Breast Cancer in New Jersey: A Registry-Based Study
by: Nicholas Acuna, et al.
Published: (2021-05-01)

Distribution And Clinicopathological Features Of Breast Cancer Histological Subtypes In Latvia
by: Srebnijs Andrejs, et al.
Published: (2015-04-01)

The maximum standardized uptake value of <sup>18</sup> F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer
by: Zhang Jian, et al.
Published: (2013-01-01)

PROGNOSTIC ROLE OF MOLECULAR SUBTYPES OF COLON CANCER. A CURRENT VIEW ON THE PROBLEM
by: L. E. Sinyansky, et al.
Published: (2021-06-01)

Significance of Oncotype DX 21-Gene Test and Expression of Long Non-Coding RNA MALAT1 in Early and Estrogen Receptor-Positive Breast Cancer Patients
by: Huang Z, et al.
Published: (2021-01-01)

Oncotype DX: Where Does It Stand in India?
by: Atul Batra, et al.
Published: (2019-07-01)

Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?
by: T. M. Aherne, et al.
Published: (2020-04-01)

Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer
by: Antonia K Roseweir, et al.
Published: (2020-10-01)

Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
by: McVeigh TP, et al.
Published: (2017-05-01)

Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer
by: Mi Jeong Kwon, et al.
Published: (2019-07-01)

Multi-field-of-view strategy for image-based outcome prediction of multi-parametric estrogen receptor-positive breast cancer histopathology: Comparison to Oncotype DX
by: Ajay Basavanhally, et al.
Published: (2011-01-01)

Oncotype Dx Results in Multiple Primary Breast Cancers
by: Michael J. Toole, et al.
Published: (2014-01-01)

Oncotype Dx Results in Multiple Primary Breast Cancers
by: Michael J. Toole, et al.
Published: (2014-01-01)

Relationship of established risk factors with breast cancer subtypes
by: Anne Marie McCarthy, et al.
Published: (2021-09-01)

The Relationship Between Anti-Hypertensive Drugs and Cancer: Anxiety to be Resolved in Urgent
by: Rong Yang, et al.
Published: (2020-12-01)

Recurrent Breast Cancer Following Modified Radical Mastectomy and Risk Factors
by: Noufel Sh. Mutlak, et al.
Published: (2012-10-01)

Utilization of Oncotype DX in an Inner City Population: Race or Place?
by: Amber A. Guth, et al.
Published: (2013-01-01)

Association Between Serum Carcinoembryonic Antigen Levels at Different Perioperative Time Points and Colorectal Cancer Outcomes
by: Zhenhui Li, et al.
Published: (2021-10-01)

Identification of Novel Metabolism-Associated Subtypes for Pancreatic Cancer to Establish an Eighteen-Gene Risk Prediction Model
by: Yang Gao, et al.
Published: (2021-08-01)

Identification of 5-methylcytosine-related signature for predicting prognosis in ovarian cancer
by: Lei Wang, et al.
Published: (2021-06-01)

Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population
by: Mustapha Abubakar, et al.
Published: (2018-09-01)

Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries
by: Junjie Huang, et al.
Published: (2021-01-01)

Comparison of breast cancer risk factors among molecular subtypes: A case‐only study
by: Liwen Zhang, et al.
Published: (2019-04-01)

KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer
by: Hendrik Jütte, et al.
Published: (2021-05-01)

Recurrence Risk after Radical Colorectal Cancer Surgery—Less Than Before, but How High Is It?
by: Erik Osterman, et al.
Published: (2020-11-01)

Correlation of Clinicopathological Characteristics of Breast Carcinoma and Depression
by: Milena B Ilic, et al.
Published: (2019-09-01)

Coexisting Germline <i>CHEK2</i> and Somatic <i>BRAF</i><sup>V600E</sup> Mutations in Papillary Thyroid Cancer and Their Association with Clinicopathological Features and Disease Course
by: Danuta Gąsior-Perczak, et al.
Published: (2019-11-01)

Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin+ cell abundance
by: Quan Zhou, et al.
Published: (2020-01-01)

The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX® Recurrence Score in ER-Positive Invasive Breast Cancers
by: Pascale A. Cohen, et al.
Published: (2019-05-01)